Advertisement

Contemporary Research on Renal Cell Carcinoma

Basic and Clinical Developments

  • Gerd Staehler
  • Sigmund Pomer
Conference proceedings

Table of contents

  1. Front Matter
    Pages I-XII
  2. Clinical Research

  3. Basic Research

    1. Front Matter
      Pages 67-67
    2. E. R. Zabarovsky, V. I. Kashuba, Z. Marcsek, E. S. Pokrovskaya, V. Zabarovska, I. Kholodnyuk et al.
      Pages 69-79
    3. H. Brauch, T. Schadt, T. Hieronymus, D. Komitowski, S. Pomer
      Pages 80-89
    4. T. Strohmeyer, W. Levin, M. Press, P. Effert, D. Slamon
      Pages 90-96
    5. H.-J. H. Decker, S. Klauck, D. I. Smith, C. Huber, B. Seizinger
      Pages 97-103
    6. C. Krüger, I. L. Noronha, H. Stein, R. Waldherr
      Pages 104-111
    7. O. G. Segurado, I. Durinovic-Bello, R. Oberneder, M. Kriegmair, A. Hofstetter, G. Riethmüller et al.
      Pages 112-120
    8. J. van Dijk, A. J. M. C. Beniers, J. A. Schalken, G. J. Fleuren, S. O. Warnaar
      Pages 132-140
    9. S. Pomer, G. Graschew, H. Sinn, T. Kälble, G. Staehler
      Pages 148-155
  4. Back Matter
    Pages 157-158

About these proceedings

Introduction

The management of advanced renal cell carcinoma is still problematic. Surgery, although the therapy of choice for locally advanced renal tumors, is still controversial as the treatment for metastases. The role of surgery in the management of patients with pulmonary, bony, and liver metastasis is one of the subject matters discussed in this book. Our results with series of patients undergoing resection of metastases from the lung, bone, and liver show that surgery may be appropriate in selected patients with a good performance status, although most of them certainly cannot be cured by this procedure alone, i.e., in the absence of effective adjuvant therapies. As recent developments show, new strategies for immunotherapy of renal cell carcinoma represent a modest advance over traditional approaches in the treatment of this cancer, such as chemo- and radiotherapy. Clinical trials employing recombinant interferon-a and interleukin 2 produced response rates in up to 30% of patients treated, as evidenced by the European Immunotherapy Trials Program. The adverse reactions and the lack of efficacy in the majority of patients warrants the search for new immunotherapeutic approaches.

Keywords

Nierenkrebs cancer cancer therapy carcinoma cell immunotherapy interferon kidney laser liver lymphocytes metastasis renal cell carcinoma surgery tumor

Editors and affiliations

  • Gerd Staehler
    • 1
  • Sigmund Pomer
    • 1
  1. 1.Abteilung Urologie und PoliklinikChirurgische UniversitätsklinikHeidelbergGermany

Bibliographic information

  • DOI https://doi.org/10.1007/978-3-642-78609-9
  • Copyright Information Springer-Verlag Berlin Heidelberg 1994
  • Publisher Name Springer, Berlin, Heidelberg
  • eBook Packages Springer Book Archive
  • Print ISBN 978-3-642-78611-2
  • Online ISBN 978-3-642-78609-9
  • Buy this book on publisher's site